Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 8/20 | 0.48 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12305790 | 0.88 | MAPKAPK5 (0.48) | MAPKAPK5CDK4CCND1CDK2FYN | |
| SCHEMBL1570305 | 0.83 | SYK (0.43) | MAPKAPK5FYNTTK | |
| SCHEMBL1476080 | 0.77 | MAPKAPK5 (0.67) | MAPKAPK5KDM1A | |
| SCHEMBL2220398 | 0.74 | MAPKAPK5 (0.54) | MAPKAPK5CDK2FYNKDM1A | |
| SCHEMBL1475749 | 0.74 | MAPKAPK5 (0.54) | MAPKAPK5CDK2FYNKDM1A | |
| SCHEMBL12306164 | 0.72 | MAPKAPK5 (0.61) | MAPKAPK5CDK4CCND1CDK2CHEK1 | |
| SCHEMBL13615999 | 0.72 | MAPKAPK5 (0.42) | MAPKAPK5FYNTTK | |
| SCHEMBL1476141 | 0.72 | MAPKAPK5 (0.51) | MAPKAPK5CDK2FYN | |
| SCHEMBL1674234 | 0.71 | MAPKAPK5 (0.66) | MAPKAPK5FYN | |
| SCHEMBL1674193 | 0.71 | FYN (0.66) | MAPKAPK5FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, PTGER1 | MAPKAPK5 131/4885CDK4 207/4885CCND1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.